{"id":"ada-011","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{"Pregnancy":"null","Paediatric use":"null","Renal impairment":"null","Hepatic impairment":"null"},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT05601219"],"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[{"date":"2024","type":"negative","milestone":"Phase 1 Initiated","description":"A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors — Solid Tumor, Adult. Trial terminated early."}],"aiSummary":"ADA-011 is an investigational drug in Phase 1 trials for advanced solid tumors. No mechanism of action or efficacy data are provided in the source.","brandName":"ADA-011","companyId":"unknown","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"Monoclonal antibody","drugClass":"","explanation":"ADA-011 is an experimental therapy currently being evaluated in early-stage clinical trials. It is being investigated for use in patients with advanced solid tumors, which are cancers that have spread beyond their original site. The drug is in the earliest phase of human testing, where researchers are primarily focused on determining safe dosage levels and initial signs of effectiveness.","oneSentence":"ADA-011 is being tested in a Phase 1 trial for patients with advanced solid tumors.","technicalDetail":"No mechanism of action or molecular target information is provided in the source text. As an investigational agent in Phase 1 development, ADA-011's specific pathway interactions, selectivity profile, and molecular targets remain undefined in the available documentation."},"commercial":null,"references":[],"biosimilars":[],"companyName":"","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"}],"genericName":"ADA-011","indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05601219","phase":"Phase 1","title":"A Phase 1, Open-Label, Multicenter Study of ADA-011 as Monotherapy and in Combination With a Checkpoint Inhibitor for Subjects With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Adanate, Inc","isPivotal":false,"enrollment":46,"indication":"Solid Tumor, Adult","completionDate":"2024-10-30"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Monoclonal antibody","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}